These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Pilot study of 2-pyrrolidon-acetamid (generic name: piracetam) (author's transl)]. Tacke B; Freistein H; Kempf H; Windheuser A Pharmakopsychiatr Neuropsychopharmakol; 1975 Mar; 8(2):82-9. PubMed ID: 788004 [TBL] [Abstract][Full Text] [Related]
24. Pimozide in the maintenance treatment of apathetic and emotionally withdrawn schizophrenics. Cheadle AJ; Freeman HL Curr Med Res Opin; 1979; 6(1):35-43. PubMed ID: 378556 [TBL] [Abstract][Full Text] [Related]
25. Phenylethylamine-like properties of baclofen. Wolf ME; Keener S; Mathis P; Mosnaim AD Neuropsychobiology; 1983; 9(4):219-22. PubMed ID: 6646393 [TBL] [Abstract][Full Text] [Related]
26. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Gulmann NC; Bahr B; Andersen B; Eliassen HM Acta Psychiatr Scand; 1976 Oct; 54(4):287-93. PubMed ID: 793304 [TBL] [Abstract][Full Text] [Related]
27. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Ceulemans DL; Gelders YG; Hoppenbrouwers ML; Reyntjens AJ; Janssen PA Psychopharmacology (Berl); 1985; 85(3):329-32. PubMed ID: 3923519 [TBL] [Abstract][Full Text] [Related]
28. A quantitative EEG analysis of the effects of baclofen on man. Badr GG; Matousek M; Frederiksen PK Neuropsychobiology; 1983; 10(1):13-8. PubMed ID: 6657034 [TBL] [Abstract][Full Text] [Related]
29. Naltrexone in chronic schizophrenia. Results of a clinical trial. Ragheb M; Berney S; Ban T Int Pharmacopsychiatry; 1980; 15(1):1-5. PubMed ID: 6993401 [TBL] [Abstract][Full Text] [Related]
30. Nicotinic acid in the prevention and treatment of methionine-induced exacerbation of psychopathology in schizophrenics. Ananth JV; Ban TA; Lehmann HE; Bennett J Can Psychiatr Assoc J; 1970 Feb; 15(1):15-20. PubMed ID: 4906138 [No Abstract] [Full Text] [Related]
31. Antipsychotic effects of ceruletide in chronic schizophrenia. An appraisal of the long-term, intermittent medication of ceruletide in chronic schizophrenia. Moroji T; Itoh K; Itoh K Ann N Y Acad Sci; 1985; 448():518-34. PubMed ID: 3927809 [No Abstract] [Full Text] [Related]
33. An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Rosse RB; Schwartz BL; Leighton MP; Davis RE; Deutsch SI Clin Neuropharmacol; 1990 Aug; 13(4):348-54. PubMed ID: 2145067 [No Abstract] [Full Text] [Related]
34. Environmental and familial predictors of attention behavior in chronic schizophrenics. Orzack MH; Kornetsky C J Psychiatr Res; 1971 Dec; 9(1):21-9. PubMed ID: 5143853 [No Abstract] [Full Text] [Related]
35. Gabergic compounds and schizophrenia. van den Berg CJ Lancet; 1976 Dec; 2(7998):1301-2. PubMed ID: 63774 [No Abstract] [Full Text] [Related]
36. Letter: Bacloffen in schizophrenia. Davis KL; Hollister LE; Berger PA Lancet; 1976 Jun; 1(7971):1245. PubMed ID: 58291 [No Abstract] [Full Text] [Related]
37. Sensory integration with chronic schizophrenics: a pilot study. Levine I; O'Connor H; Stacey B Can J Occup Ther; 1977 Mar; 44(1):17-21. PubMed ID: 10236149 [No Abstract] [Full Text] [Related]
38. Pyridoxine and schizophrenia. Bucci L Br J Psychiatry; 1973 Feb; 122(567):240. PubMed ID: 4714839 [No Abstract] [Full Text] [Related]
39. Baclofen at the end of life. Lee RL; Koay T; Miller M BMJ Support Palliat Care; 2023 Sep; 13(3):313-314. PubMed ID: 37595971 [No Abstract] [Full Text] [Related]
40. Opportunities and needs in digital phenotyping. Marsch LA Neuropsychopharmacology; 2018 Jul; 43(8):1637-1638. PubMed ID: 29703995 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]